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PROVIDER PRACTICES IN THE MANAGEMENT OF PRIMARY 
HYPOTHYROIDISM DUE TO AUTOIMMUNE THYROIDITIS 
CARISSA IKKA PARDAMEAN 
ABSTRACT 
Thyroid hormone is a master regulator of growth and development in all vertebrates. 
Thus, disruption of its synthesis and activity can lead to profound consequences. Past 
decade studies on thyroid function tests have established an efficient guideline for 
monitoring thyroid diseases, yet a significant proportion of healthcare providers do not 
defer to it in their practice. The aim of this study is to assess provider practices in the 
diagnosis and treatment of primary hypothyroidism due to autoimmunity at Boston 
Children's Hospital (CHB) for a primarily pediatric patient population. Commonly known 
as Hashimoto's thyroiditis (HT), this is the most common thyroid disease in the world as 
well as the most common manifestation of human autoimmune endocrine disease. 
Through CHB's bioinformatics institute, a rich data set was collected to assess the 
manner in which healthcare providers utilized relevant thyroid function tests (TFTs). This 
work assessed and confirmed the superior sensitivity of thyroid peroxidase autoantibodies 
(TPO) relative to thyroglobulin antibodies (TgAb) for diagnosing HT in children. We also 
verified proper utilization of thyroid stimulating hormone tests to monitor HT but 
concluded that there is a low utilization efficiency with regards to measurements of 
thyroid hormones (thyroxine and triiodothyronine). Based upon the observation of 
unnecessary monetary loss caused by improper TFTs utilization, it can be concluded that 
reflex testing at CHB may improve provider practices' efficiency for HT monitoring. 
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INTRODUCTION 
All vertebrates produce thyroid hormone (TH), a tyrosine-based hormone with an all-
encompassing and comprehensive role of initiating and sustaining an organism's 
development, proliferation, growth, and the most integral role of all, the maintenance of 
proper tissue and cellular metabolism. With the necessity of TH's biologic effects in 
virtually every organ system within the body, any disruption on thyroid function can lead 
to a wide-array of cascading problems; the myriad of negative consequences range from a 
child's inability to thrive physically and cognitively to an adult's lowered quality of life 
due to abnormal metabolic rate to an elderly person's rapid descent into osteoporosis due 
to imbalanced skeletal maintenance. Thus, preventing and treating thyroid-related 
complex diseases would require a pertinent, fundamental understanding of the thyroid 
system as well as proper application of thyroid function knowledge within the clinical 
setting. 
 
Thyroid Hormone 
 Biochemically, TH is derived from the amino acid tyrosine, coupled with iodine; 
thus, dietary iodine intake has a significant role in regulating TH synthesis. However, the 
production of TH is primarily under the control of the hypothalamic-pituitary-thyroid 
axis (HPT axis; Figure 1) through negative feedback regulation (Molina, 2013). The 
hypothalamus produces thyrotropine/TSH releasing hormone (TRH), which binds its 
receptors in the anterior pituitary, signaling it to release thyroid stimulating hormone 
(TSH) via exocytosis into the systemic circulation. TSH then triggers the synthesis of TH 
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within the thyroid gland as well as its secretion, as triiodothyronine (T3) and thyroxine 
(T4), into the systemic circulation (Molina, 2013). The HPT axis's signal for TSH release 
receives negative feedback from T3, primarily through T4 to T3 conversion within the 
hypothalamus as well as several deiodination pathways in the anterior pituitary. These T3 
conversions play a greater role in negative feedback than does the T3 within the 
circulation (Molina, 2013).  
 TSH's binding to its receptor in the thyroid gland leads to the initiation and 
activation of a protein kinase A signaling cascade with the eventual result of iodine 
uptake and organification as well as the transcription of several genes involved in TH 
production (Molina, 2013). Amongst the gene products are: 
 Sodium-iodine (Na+/I-) symporter, involved in the transportation and 
concentration of iodide in the thyroid epithelial cell;  
 Thyroglobulin (Tg), the glycoprotein that scaffolds tyrosine residues used for TH 
synthesis; 
 Thyroid peroxidase (TPO), the enzyme involved in catalyzing iodide oxidation 
and incorporation into tyrosine residues of Tg. 
For this reason, the TSH receptor is a frequent target for aberrant antibodies, leading to 
thyroid autoimmune disease. Autoantibodies can mimic the actions of TSH with both 
agonist or antagonistic roles (Nussey & Whitehead, 2001). 
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Figure 1. Schematic Depiction of Hypothalamus-Pituitary-Thyroid Axis (Adapted 
from Bartke & Hiller-Sturmhöfel, 1998) 
 
 The biochemistry of TH synthesis begins with Tg's multiple tyrosine residues. Tg 
is synthesized within the thyroid follicular epithelial cell before its secretion into the 
follicular lumen’s apical side for further modification. Tg's tyrosine residues are then 
iodinated by I+ (formed via the oxidation of I- by TPO), a process called organification 
(Molina, 2013). This yields monoiodinated tyrosine (MIT) and diiodinated tyrosine 
(DIT). The coupling of MITs and DITs form T3 and T4, which is facilitated by TPO. The 
iodine needed for TH synthesis is absorbed from dietary sources, such as iodized salt, 
seafood, and plants grown in iodine-rich soil. Absorbed iodine is then confined within the 
extracellular fluid with 1/5 removed by the thyroid gland for TH production while the rest 
is excreted by the renal system. The saturation of iodine in the thyroid epithelial cells is 
TSH regulated and mediated by the Na+/I- symporter (Molina, 2013). 
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 Aside from its crucial role in the synthesis of TH, TSH also holds an essential role 
in controlling the release of TH from the thyroid gland. TSH signals the endocytosis of 
vesicles within the follicular cell and the cleavage of TH from Tg; this scaffolding feature 
to Tg allows for the gland's ability to maintain up to three months' supply of TH. Once 
cleaved from the Tg pool, TH is released in both T4 and T3 forms (Molina, 2013). The 
thyroid gland releases greater amounts of T4 than T3 into the systemic circulation, 
leading to a forty-fold higher concentration of T4 than that of T3. Most peripheral T3 is 
produced from the deiodination of T4 within the liver (Nussey & Whitehead, 2001). 
Despite the much lower concentration, T3 is more active than T4 in terms of biologic 
activity due to T4's much lower affinity for TH receptors compared to that of T3. Within 
the circulation, most T4 and T3 is bound to proteins, such as thyroid-binding globulin and 
albumin, with a small fraction circulating in free form. T4 binds to proteins much more 
tightly than T3 does, leading to a longer half-life and lower clearance for T4 (Molina, 
2013). 
 The activity of TH is present in virtually every organ, specifically with regards to 
regulating the metabolic rate of that organ. The specific mechanism with which TH 
maintains these rates differs from one tissue to another. For instance, other than in the 
brain, spleen, and testis, TH, through a variety of mechanisms, increases an organ's 
metabolic rate through the increase of mitochondria's production and size. This 
mitochondrial amplification can be accompanied by amplification in the production of 
proteins and enzymes involved in the respiratory chain (Nussey & Whitehead, 2001). 
Major roles of TH can be found within the cardiovascular system, fat tissues, brain, and  
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Table 1. Common Clinical Presentations of TH Imbalance with Laboratory Values 
 (Amended based on Molina, 2013) 
 
Hypothyroidism Hyperthyroidism 
Clinical 
Presentation 
Laboratory 
Values 
Clinical Presentation Laboratory 
Values 
Fetal Development: 
Cretinism, mental 
and growth 
retardation 
 
Adult Acute: 
Lethargy, 
constipation, 
decreased appetite, 
cold intolerance, 
hair loss, dry coarse 
skin, hoarse voice, 
abnormal menstrual 
flow 
 
Chronic: 
Thickened features, 
myxedema, delayed 
muscle contraction 
and relaxation, 
reduced reflexes, 
decreased cardiac 
output, enlarged 
heart, slowing 
mental function, 
impaired memory 
and speech rate, 
hypothermia 
Primary: 
High TSH 
Low free T4 
Low/Normal T3 
 
Secondary: 
Low TSH, T4, T3 
Palpitations, 
tachycardia at rest and 
during exercise, 
increased blood 
volume, palpable 
enlarged thyroid gland, 
hyperactivity, infiltrative 
ophthalmopathy, heart 
pounding, heat 
intolerance, weight loss, 
increased metabolic 
rate, fine tremor, 
excessive sweating, 
decreased or absent 
menstrual flow, warm 
and moist skin, 
proximal muscle 
weakness, fine hair 
Primary: 
Low TSH  
High T4 
High T3 
 
Secondary: 
High TSH, T4, T3 
 
 
liver. In many cases, TH manages crucial gene expression, such as genes involved in 
myelination of neurons within the brain and genes that produce channels important in 
maintaining cardiac activity (Molina, 2013). Besides controlling gene expression, TH 
also tends to have a more indirect modulatory role of activating signaling cascades, such 
as the ones involved in adipose reserve maintenance and in liver cell proliferation. TH is 
also important for normal growth and development, especially in neonates and children. 
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TH plays a crucial role in balancing the activities of osteoclasts and osteoblasts within 
bone tissues. An imbalance in children leads to growth defects while a deficiency in 
adults leads to an increased risk for osteoporosis (Molina, 2013; Nussey & Whitehead, 
2001). 
 Due to the multi-faceted and ubiquitous nature of TH in terms of target organs, an 
imbalance could lead to multiple effects. Listed in Table 1 above are the more common 
clinical presentations of TH imbalance and the laboratory values attached to them, 
illustrating the expansive nature of TH's role within the body. 
 
Hypothyroidism 
 Hypothyroidism is a thyroid disorder due to an insufficiency of thyroid hormone 
function. It is the most common thyroid disease in the world (Braverman & Utiger, 
2005). Based on its etiology, hypothyroidism can be categorized according to the source 
of the dysfunction. Primary hypothyroidism is the most common form of this 
categorization, contributing to 95% of hypothyroidism observed within a clinical setting. 
Its etiology leads to a defect in the production or release of thyroid hormone by the 
thyroid gland itself (McDougall, 1992). Secondary and tertiary hypothyroidism are 
caused by a dysfunction in the central-thyroid axis required by the thyroid gland to 
perform its proper function; the former due to a pituitary-thyroid axis dysfunction and the 
latter due to a hypothalamus-thyroid axis dysfunction. Along with quaternary 
hypothyroidism, which is caused by peripheral resistance to thyroid hormones, these are 
the rarer forms of hypothyroidism (McDougall, 1992). Based on severity as inferred 
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through thyroxine levels, hypothyroidism can be categorized as clinical/overt and 
subclinical/mild. Both forms have hyperthyrotropinemia (high level of serum thyroid 
stimulating hormone) but only clinical hypothyroidism results in a low level of free 
thyroxine while subclinical retains a normal free thyroxine level (Almandoz & Gharib, 
2012; McDougall, 1992).  
 The most commonly cited statistics for the prevalence of hypothyroidism is based 
on an analysis of the NHANES III on the US population from 1988-1994, stating a 4.6% 
prevalence of all forms of hypothyroidism, with 0.3% for clinical hypothyroidism's 
contribution to the statistics (Golden et al., 2009; Hollowell et al., 2002). A more updated 
analysis based on the 1999-2002 NHANES reports a prevalence of 3.7% overall but 
clinical hypothyroidism remains at 0.3% (Aoki et al., 2007). A brief overview of the 
epidemiology of hypothyroidism indicates that women and non-Caucasian 
subpopulations have a higher prevalence and risk for developing hypothyroidism. The 
risk also increases with age, leading to a higher prevalence in the elderly subpopulation 
(Almandoz & Gharib. 2012; Aoki et al., 2007; Hollowell et al., 2002). 
 The treatment of hypothyroidism is in the form of hormone replacement therapy 
and dates back to more than a century ago, when sheep thyroid extract was used for 
management. It is highly effective, cheap, and easy to manage, especially since the ability 
to monitor thyroid profiles allows for the mimicry of normal thyroid physiology (Woeber, 
2005; Nussey & Whitehead, 2001). A variety of pharmacologic preparations are available 
on the market, including levothyroxine (L-T4), liothyronine (L-T3), liotrix (1:4 T3 and 
T4 combination). However, as mentioned before, T3 is the much more active form of TH 
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but is present in the circulatory system at a much lower concentration for a shorter period 
of time (faster clearance) when compared to T4. Thus, the most effective treatment of 
hypothyroidism is to administer T4 to serve as the prohormone to T3 production in the 
peripheral tissues, especially considering the fact that 80% of T3 production occurs in 
these tissues rather than the thyroid gland (Woeber, 2005). Combination T3:T4 drugs 
result in a small to no efficacy difference so that synthetic levothyroxine remains the best 
treatment for hypothyroidism (Almandoz & Gharib, 2012). 
 
Figure 2. Serum TSH and Free T4 Negative Logarithmic-Linear Relationship 
 (Adapted from Fish et al., 1987) 
 
 The goal of hormone replacement treatment is to achieve normal thyroid levels, 
leading to the resolution of clinical symptoms. The monitoring of treatment can be done 
simply through periodic measurements of TSH, typically every 6-12 months. The 
negative logarithmic-linear relationship between TSH and free T4 (Figure 2) depicts 
TSH's higher sensitivity relative to T4 in indicating thyroid function changes. 
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 After the therapy adjustment period of 2-3 months, a patient's thyroid profile 
should begin to improve with clinical symptom resolution lagging behind for a month or 
two. Certain groups of patients require special attention for management, due to 
differences in T4 bioavailability caused by other factors. Commonly considered factors 
include but are not limited to, patients who are elderly, pregnant, or receiving treatment 
for certain cardiac diseases (Woeber, 2005) though more recent studies are increasingly 
suggesting that age is not a crucial factor in determining T4 bioavailability and treatment 
adjustments (Almandoz & Gharib, 2012). 
 Despite the effectiveness of hormone therapy, the actual practice to provide 
optimal treatment to patients is much more complex, with a variety of factors 
contributing to the mosaic of hypothyroidism monitoring. The most basic factor is the 
fact that hypothyroidism is often times a chronic disease that requires lifelong 
management. An individual's physiology may change over time, which calls for a 
corresponding adjustment of hormone treatment, e.g. the need for dosage adjustment due 
to weight change in a patient (Somwaru et al., 2009). Genetic, environmental, and 
presence of other diseases also contribute to the variability in response to treatment, 
necessitating tailoring and close monitoring of therapy for individual patients. Having 
proper knowledge on how to handle these variables becomes crucial, calling for the 
expertise of a thyroid specialist. However, there is an emerging trend of placing 
hypothyroidism monitoring responsibilities on primary care physicians and general 
practitioners (rather than thyroid specialists). The reason is simply that the thyroid 
specialist to hypothyroid patient ratio is low. This becomes problematic since many 
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general practitioners have voiced their concerns on having inadequate knowledge on how 
to properly utilize many specific laboratory tests, including those relevant for monitoring 
thyroid function (Okosieme et al., 2010; Kratz & Laposata, 2002).  
 One study reports that on average, only 40-60% of diagnosed hypothyroid 
patients taking hormone replacements are properly treated, as indicated by the 
maintenance of euthyroidism. This means that a significant portion of the hypothyroid 
patients are either under or over treated. The cited reasons for this are poor compliance, 
improper dosage prescriptions, and drug interaction. Over-treatment poses adverse risks, 
especially in the cardiovascular and skeletal systems; in particular, an increased risk for 
atrial fibrillation, osteoporosis, and bone fractures. On the other hand, poorly managed 
hypothyroidism is associated with chronic body weight problems as well as damaging 
effects on lipid profiles and blood pressure (Okosieme et al., 2010). A study on the 
pediatric population shows that uncorrected hypothyroidism in children is associated with 
impaired/lowered cognitive function, and this effect is detected in children by the time 
they reach 11 years of age. However, this is associated more significantly with over-
treatment than under-treatment of hypothyroidism (Bongers-Schokking et al., 2013). 
 
 Primary Hypothyroidism 
 The most common cause of primary hypothyroidism in the world is iodine 
deficiency, leading to a defect in TH synthesis. Radiation treatments, surgical removal of 
thyroid gland (thyroidectomy), infiltrative diseases (such as scleroderma) and congenital 
defects can all lead to primary hypothyroidism but have a much smaller contribution as 
an underlying cause of primary hypothyroidism (Braverman & Unger, 2005). For this 
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study, the focus was on a form of primary hypothyroidism caused by autoimmunity called 
Hashimoto's thyroiditis. Also known as chronic autoimmune thyroiditis, this is the most 
common cause of primary hypothyroidism in populations with fulfilled iodine 
requirements, making it the most common cause of primary hypothyroidism in the United 
States (Almandoz & Gharib, 2012). 
 
Hashimoto's Thyroiditis (HT) 
 
 HT Epidemiology 
 Hashimoto's thyroiditis (HT) is the most common clinical manifestation of 
autoimmune thyroid diseases (AITD) and leads to hypothyroidism. AITD is the most 
common autoimmune endocrine disease, as well as the most common autoimmune 
disease in the United States (Tomer, 2010) with an average prevalence of 5% for a given 
population anywhere in the world. The contribution of HT to this prevalence varies based 
on the decade when the study was done and the demographics of the population 
investigated (Dayan & Daniels, 1996; Hasham & Tomer, 2012).  
 HT has the highest prevalence within the age range of 30-50 years, with the risk 
of manifestation increasing with age, paralleling that of overall primary hypothyroidism's 
epidemiology (Dayan & Daniels, 1996). The worldwide incidence of HT per annum is 
estimated to be between 0.3 to 1.5 cases per 1000 persons. In the United States, the 
estimated incidence of HT is 1.3% in children between the ages of 11 to 18 years old. In 
adults, the incidence is 3.5 new cases per 1000 per annum in women but 0.8 per 1000 per 
annum in men, reflecting the statistics that HT heavily presents in women. The range of 
 12 
HT prevalence falls between 1-2% in women while the men's prevalence is only a 
fraction, anywhere between 1/5 to 1/10, of the corresponding women population's 
statistics (Staii et al., 2010). 
  
 HT Etiology 
 HT is a complex disease, with both genetic and environmental factors affecting an 
individual's susceptibility and the development of disease(Eschler et al., 2011). The first 
major histocompatibility complex (MHC) gene region associated with both HT and 
Graves's Disease (GD, the other manifestation of AITD, resulting in hyperthyroidism) is 
from the HLA Class II gene, specifically the HLA-DR allele. The polymorphic nature of 
HLA leads to many of its alleles having significant roles in different autoimmune 
diseases, making it a proper candidate gene for finding a genetic cause for AITD 
(Hasham & Tomer, 2012). However, genetic association studies show that the HLA-DR 
allele is not as significantly associated with HT as it is with GD (Eschler et al., 2011). 
Nevertheless, more recent investigations from a structural biology angle have recouped 
this link by establishing a strong association between HT and the HLA-DR allele 
(Eschler et al., 2011; Hasham & Tomer, 2012).  
 The link between HLA-DR and HT is recapitulated by the discovery that the HLA 
glycoprotein produced by HLA-DR possesses a more positive protein binding pocket 
(due to an alanine or glycine substitution with an arginine). This subsequently leads to a 
change in binding selectivity, favoring autoantigenic peptides. In the case of HT, the 
autogenic peptides are commonly derived from thyroid peroxidase (TPO) and 
thyroglobulin (Tg) (Eschler et al., 2011; Hasham & Tomer, 2012). 
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 Several non-MHC genes are also associated with HT (Eschler et al., 2011). The 
more commonly studied genes fall into one of two categories: immunoregulatory and 
thyroid-specific. Two well-investigated immunoregulatory genes associated with HT are 
the CTLA-4 gene and PTPN 22 gene. Both major alleles of these genes negatively 
modulate T-cell activity and proliferation through suppression and inhibition. Thus, 
associated alleles result in the loss of this negative modulatory role. Another non-MHC 
gene group contains thyroid-specific genes. For HT, the most significant one is the 
thyroglobulin gene (Tg gene) since Tg is a key antigen in HT's pathology (Eschler et al., 
2011). The link and synergy between MHC and non-MHC genes leading to HT is still 
unclear. However, there is a significant inferred association between certain Tg gene 
alleles and the MHC gene's HLA-DR allele in terms of co-occurrence. Since early 
genome-wide association studies on HT in the 1980s, this Tg-HLA gene link has been 
qualitatively determined through the frequent observation of heightened autoimmunity in 
animal models that possess both the HLA-DR allele and a Tg-gene allele of HT-interest, 
relative to animals with only one or the other (Rose, 2011). With more recent 
advancements in computational biology and biostatistics, this association has been 
quantified and found to be significant and strong (Eschler et al., 2011). 
 The environmental contribution towards HT varies according to the studied 
population, much like its prevalence. Potential environmental mechanisms leading to HT 
range from direct toxicity towards thyroid cells to immune system over-stimulation to 
interference with thyroid activity and function (Hasham & Tomer, 2012). The following 
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are the most commonly discussed and more widely studied environmental factors 
influencing susceptibility for HT (Eschler, 2011; Hasham & Tomer, 2012): 
 Iodine intake. Due to the crucial role of iodine in thyroid hormone synthesis, this 
is one of the most studied factors, especially within an epidemiological setting, 
e.g. to correlate and associate iodine intake levels with the prevalence and 
susceptibility for certain thyroid diseases. HT is associated more heavily with 
excess intake of iodine. 
 Medication. Amiodarone is the medication that is most studied for HT due to the 
fact that it is an iodine-rich drug for managing tachyarrythmia. Other medications 
include those that fall within the categories of antiretroviral and interferon-α 
treatments. Both classes are thought to play a role in over activating the T-cell 
population in an individual's thyroid gland as an adverse side effect.  
 Infectious agents. Particularly from viruses and to a certain extent, bacteria. The 
viral infection most associated with HT is Hepatitis C (for which interferon-α is a 
treatment). Bacterial infection is less studied but is an emerging field. The most 
oft-associated bacterial infection is from gastrointestinal dysbiosis, or the loss of 
normal balance of gut microbiota (Mori et al., 2012). While other autoimmune 
diseases have been studied with more depth within the context of gut microbiota, 
the studies on HT are sparse and recently emerging. The enterobacteria of the GI 
tract play a key role in maintaining the balance between immune activation and 
immune tolerance in the gut-associated lymphoid tissue (GALT). Thus, the 
disruption of gut microbiota may have negative repercussions towards the balance 
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of GALT activities and subsequently, the immune tolerance in an individual's 
thyroid gland (Mori et al., 2012). 
 Environmental toxins. Toxins are more associated with GD rather than HT. 
However, organic chemicals that fall into the polyhalogenated biphenyls (PBB) 
class are particularly linked to HT susceptibility. Individuals exposed to PBB on a 
regular basis are found to have consistently high levels of antimicrosomal 
antibodies as well as anti-thyroid peroxidase and anti-thyroglobulin antibodies; all 
of which are hallmark indicators for HT diagnosis. 
  
 Monozygotic twin studies have indicated that 79% of attributed causes of HT are 
genetic-based (Hasham & Tomer, 2012) while dizygotic twin studies estimate a lower 
genetic contribution, up to 50% at most, indicating the importance of environmental 
contribution in the etiology of HT (Hiromatsu et al., 2013). The interactions between 
genetic and environmental factors are still unclear as well, calling for further studies on 
epigenetic contributions (Hasham & Tomer, 2012). 
 
 HT and Clinical Presentation 
  The cellular mechanism that leads to hypothyroidism is the improper function of 
the immune system, leading to the activation of CD4 T-helper cells by the thyroid; this 
trigger mechanism performed by the thyroid unto itself is still unclear (Dayan & Daniels, 
1996; Hiromatsu et al., 2013). Self-reactive CD4 cells then recruit toxic CD8 T-cells and 
autoreactive B-cells into the thyroid gland (lymphocytic infiltration) with three main 
targets: thyroid peroxidase, thyroglobulin, and thyroid stimulating hormone receptor. 
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Despite the recruitment of B-cells and the presence of antithyroid antibodies against its 
targets within the thyroid, CD8 T-cells are thought to be the main mechanism responsible 
for the destruction of the thyroid gland, typically leading to hypothyroidism. More 
specifically, it was found that HT thyrocytes express the Fas gene associated with 
apoptosis, an attribute not found within normal thyroid cells (Stuart, 2012). The 
interaction of Fas with the Fas ligand on the surface of HT thyrocytes is one of the 
hypotheses for the mechanism that triggers aberrant thyroid immunity, leading to 
lymphocytic recruitment and infiltration (Stuart, 2012). Another hypothesis is that a 
specific yet unidentified antigen is responsible for initiating the aberrant immune 
response (Dayan & Daniels, 1996). 
 HT usually presents clinically through hypothyroidism, goiter, or both. Goiter is 
usually the first sign, a diffuse enlarged thyroid gland with firm consistency and irregular 
surface. Histologically, HT has a hallmark of Hurtle cells, described as enlarged follicular 
cells with finely granular nuclei and deeply acidophilic cytoplasm. The mechanism and 
trigger that cause normal thyrocytes to transform into Hurtle cells are still unclear, 
especially since there are a minority of cases in which the resected thyroid glands contain 
Hurtle cells without the accompanying lymphocytic infiltrates (Stuart, 2012). The 
aforementioned activity of Fas gene/ligand interaction is thought to precede this cell 
transformation but this order's significance is unknown (i.e. whether or not the Fas 
interaction triggers the transformation). Additionally, the signal that causes the Fas gene 
product to interact with Fas ligand is largely unknown (Stuart, 2012). 
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 HT Diagnosis 
 The typical symptom that triggers the steps for diagnosing HT is the presentation 
of a goiter accompanied by laboratory confirmation of high thyroid stimulating hormone 
level. A documentation of low serum free thyroxine would also be standard procedure, to 
confirm the differentiation between clinical and subclinical hypothyroidism. However, a 
significant proportion of HT patients initially present euthyroid laboratory measurements. 
Thus, the gold standard biochemical evidence for HT is a one-time documentation of a 
high serum titer for anti-thyroid antibodies, typically anti-TPO or anti-Tg. (Ajjan & 
Weetman, 2010; Weetman, 2005). The preferred anti-thyroid antibody for testing is anti-
TPO because 95% of HT patients present this antibody, rendering it to be the most 
sensitive test while the next most sensitive test is measurement of anti-Tg, present in only 
60% of HT cases. Normal  levels of anti-TPO antibodies could lead to anti-Tg 
measurement for thorough biochemical evidence prior to diagnosis. Despite the presence 
of standards established based on the literature, there still exists variability in an 
individual physician's protocol in diagnosing HT, especially with regards to the types of 
thyroid function tests measured to confirm the HT diagnosis (Ajjan & Weetman, 2010; 
Dayan & Daniels, 1996). 
 
 HT Monitoring 
 Much like the lack of consistency in diagnosing HT, the presence of literature-
supported standard monitoring protocols has not resulted in a uniform practice for 
primary hypothyroidism and HT monitoring. The bulk of medical care for any form of 
primary hypothyroidism, including HT, consists of routine measurements of certain 
 18 
thyroid function tests, which could lead to several adjustments, such as the frequency of 
monitoring patient condition, the prescribed hormone replacement therapy dosage, etc. 
 Many professional medical societies have their own individual guidelines on how 
to manage thyroid disorders, especially with regards to thyroid function tests (TFTs) 
(Nordyke et al., 1998). Numerous studies have accepted TSH as the most sensitive test to 
monitor HT, especially relative to T4's sensitivity. The literature also suggests that T4 
measurements be used sparingly, i.e. subsequent to the detection of a clinically significant 
change in TSH level relative to euthyroid condition or the patient's previous TSH level. 
Table 2 below summarizes the suggestions of clinical standards from the past two 
decades, depicting the evolution of HT monitoring. 
Table 2. Snapshots of Suggested Clinical Standard for Hypothyroidism and HT 
Management over Time* 
 
Source Suggested Clinical Standard 
Schectman & Pawlson (1990) Reported: ordering both free T4 and TSH 
is common practice despite suggestion 
that TSH only is highly sufficient 
 
Suggested: T4 first or TSH first at 
physicians' discretion, leaving the cost 
vs. quality problem to individual providers 
but not both as the combination is costly, 
with low yield in care improvement 
gained from T4 tests added to TSH tests 
McDougall (1992) States a preference to measure both free 
T4 and TSH although due to the need for 
repeated measurement, ordering either 
free T4 or TSH only might be simpler 
Nordyke et al. (1998) Reported: multiple health centers in 
Honolulu, Hawaii have three common 
patterns: measuring free T4 only, TSH 
only, or both 
 
Suggested: ideally, the authors suggest 
reflex testing with measuring TSH first 
then free T4 if necessary. Recognizing 
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the lack of technology needed to do so in 
many medical facilities, the authors 
suggest simultaneous testing of both free 
T4 and TSH to be the best compromise 
between quality of care and cost 
Kratz & Laposata (2002) Reported: many redundant testing of free 
T4 without notice that the initial 
documentation for hypothyroidism 
diagnosis had been done 
 
Suggested: application of the reflex 
testing model in a healthcare facility to 
test free T4 only if TSH suggests 
necessity during management of thyroid 
disease; it was found at Massachusetts 
General Hospital where the reflex testing 
model was applied that this model 
reduces testing costs 
Woeber (2005) Because of the established sensitivity of 
TSH over any form of T4 measurement, 
monitoring lifelong hypothyroid patients 
should consist mainly of periodical TSH 
measurements 
Leung & Farwell (2010) With increased testing sensitivity for TSH, 
it should be the first measurement taken 
before other thyroid function tests are 
performed 
Almandoz & Gharib (2012) Measurement of TSH first then free T4 
upon the detection of high TSH level 
 
*'Reported' is defined as what the author(s) viewed to be common practice during their 
time. 'Suggested' is defined as the protocol suggested by the author in lieu of the 
common practice at the time. 
 
 
 The recommended standard in contemporary literature is to order TSH only 
before resorting to any peripheral T4 measurements. However, in a significant proportion 
of actual clinical practice, a form of peripheral thyroxine (T4) test is ordered 
simultaneously with TSH; in the 1990s, some common practice even favored the 
measurement of T4 tests only (Nordyke et al., 1998). One of the reasons for different 
practices with regards to testing TSH versus T4 stems from earlier practices when the 
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main goal was to balance cost and quality. A TSH test was more costly but yielded a more 
accurate clinical interpretation while a T4 test was cheaper. In 1998, Nordyke et al. 
performed an analysis on the quality and cost trade-off on TSH and free thyroxine testing 
based on Medicare reimbursements for these tests. The results of their analysis suggest 
that the ideal solution would be to apply reflex testing with the TSH test ordered first then 
thyroxine tested only if necessary based on the TSH result; both would be performed on 
the same blood sample. The total cost of TSH and free T4 was $6.50 per blood sample, if 
measuring free T4 is found to be necessary. However, the cost of doing such tests without 
reflex testing would be a combination of $4.61 per free T4 test and $5.90 per TSH test 
since they would be performed from different blood samples taken from different dates of 
visitation. These are direct patient costs for those who are enrolled in the Medicare 
program. For patients who are not under Medicare, however, the cost of the tests is much 
higher. One 1990 study performed a cost analysis on T4 and TSH tests from laboratories 
in Washington, DC and found that thyroxine tests cost on average $26 while TSH tests 
cost $46 (Schectman & Pawlson, 1990). Thus, to circumvent the problem, it was 
suggested by many professional organizations in the 1990s to order both tests on the 
same blood sample, regardless of the necessity of the thyroxine result for clinical 
purposes. The solution was thought to sacrifice quality the least, at slightly higher 
monetary cost (relative to ordering TSH only or thyroxine only but lower than ordering 
the two separately) and a higher waste on laboratory resources for cases in which the T4 
test was unnecessary (Nordyke et al., 1998; Schectman & Pawlson, 1990); the latter point 
is supported by the fact that ordering TSH and T4 leads to very few additional diagnosis 
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compared to ordering TSH alone with the estimation of one patient diagnosis missed for 
every 5000 patients monitored for hypothyroidism with the TSH-only method 
(Schectman & Pawlson, 1990). 
 The other major reason for the oversight to update practice with regards to thyroid 
disorder is the lack of expertise knowledge, especially from the part of non-thyroid 
specialists. These practitioners tend to rely on a large menu of laboratory assays, ordering 
tests without understanding their purpose. This often leads to unnecessary or superfluous 
clinical laboratory measurements (Kratz & Laposata, 2002). Gupta et al. exemplify this 
problem through their institution's provider practices by observing the TFT ordering 
patterns of clinicians at Gian Sagar Medical College in Banur, India. The authors found 
that only 46% of the TFT tests ordered were for TSH only and the most common pattern 
(47.5%) was to order thyroxine, TSH, and triiodothyronine (T3) tests together. However, 
in 77% of these patients, measurement of TSH alone would have been sufficient to show 
that the patients were euthyroid and no further action was needed based on the patients' 
other clinical symptoms. The authors credit the ordering of unnecessary tests to the fact 
that almost 4/5 of the test orders came from non-specific and non-endocrine related 
departments, namely departments of medicine and gynecology where the medical teams 
tend to lack solid knowledge of thyroid disorders (Gupta et al., 2011). Primary care and 
non-specialist providers have also voiced their concerns that they are often called upon to 
provide care that is beyond their scope (one in four physicians strongly agrees with this 
statement) while also stating that when they do not possess adequate knowledge to 
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diagnose or manage a case, they are only able to obtain definitive answers 30-50% of the 
time (Kratz & Laposata, 2002). 
 
Study Objectives 
 Given the complex nature of thyroid diseases and the need for extensive clinical 
laboratory services, it would be in a hospital’s best interest to be as efficient as possible in 
dealing with thyroid diseases, particularly HT, given its high prevalence and chronic 
nature. Aside from the cost reduction and the efficient use of resources arguments, a more 
important motivation for improving HT management is its requirement for a lifelong 
treatment and management regiment, which usually means proper adjustment of a 
patient's levothyroxine (or other hormone replacement therapy) dosage. Managements 
relies heavily on laboratory measurements of thyroid function. Based on the 
aforementioned problems recognized in the literature with regards to HT management as 
well as the oft-proposed solution of reflex testing implementation for monitoring HT, this 
study aimed to: 
1. Gain knowledge concerning an effective utilization of a variety of software to 
perform data collection and analysis; 
2. Investigate provider practices for patients with HT within the clinical setting of a 
major pediatric hospital and compare them against standard practices based on the 
literature; 
 23 
3. Estimate the cost-effectiveness of the current practice in diagnosing and managing 
HT and then model how reflex testing would improve the effectiveness without 
sacrificing the quality of medical care. 
  
 This study is a part of a larger project with the objective of investigating the 
provider practices of various thyroid diseases. The aforementioned objectives render this 
study to be a form of test-run to identify and/or resolve common problems and 
limitations. Due to its high prevalence, HT provides the richest data set to test a 
software's capability and suitability, a query's accuracy, and an analysis's thoroughness. 
Therefore, this study's processes and results would generate invaluable and relevant 
knowledge to achieve the greater goal of analyzing the clinical practices of different 
thyroid dysfunctions. 
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METHODS 
 
Through the establishment of biomedical informatics and computational biology research 
institutes, investigators have the ability to conduct clinical research with ease based on 
rich data sets that could be collected according to an individual project's specifications. 
Large database management is the crux of the interaction between biomedical sciences 
and current clinical practices; clinical data informs biomedicine of the problems at-hand 
while biomedicine provides the clinical field with novel and/or improved solutions. This 
renders the work of clinical investigators in academic medical centers to be highly 
dependent on the efficiency and advancement of a bioinformatics institute's development. 
For CHB, this vital institute, Informatics for Integrating Biology and the Bedside (i2b2), 
was established in 2004 with NIH funding. With i2b2, electronic records of clinical data 
can be systematically accrued and accessed with little difficulty. In the case of this study's 
initial patient data set, the data dates back to the early 1990s. With the simplicity of the 
user interface of i2b2, utilizing the data-mining software requires minor training (Murphy 
et al., 2009). 
Initial Patient Dataset  
 The initial, general patient dataset was obtained through data-mining with i2b2's 
data querying software. Queries were run based on specific inclusion and exclusion 
criteria. This study's goal was to collect data from patients with primary hypothyroidism 
due to autoimmune thyroiditis. The inclusion and exclusion criteria were searched based 
on keywords and ICD-9 codes associated with the disorders/diagnoses while the 
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laboratory tests were retrieved through search terms. Two keywords, 'Hashimoto's 
disease' and 'chronic lymphocytic thyroiditis', as well as the ICD-9 code 245.2, were used 
to retrieve the patient population of interest. A set of exclusion criteria was also run 
within the same query (Figure 3). This investigator-based query resulted in the identifiers 
of patients (such as medical record number, full name, date of birth) who fulfilled the 
determined criteria. With this set of identifiers, an i2b2 staff retrieved the thyroid function 
tests (TFTs) needed for answering the study's questions through a software that can be 
queried only by the institute's programmers (investigators not staffed by i2b2 cannot 
initiate queries through this database as it does not have a general user's interface). An 
initial querying for the laboratory tests was done through the CPT-4 billing codes. 
However, i2b2 database was found to be more inclusive when the TFTs were searched 
through only keywords, i.e. the names of the tests. The final query is summarized in 
Figure 3. 
 The final output of the programmer-run query was a set of thyroid function tests 
with their corresponding dates and the test value/serum level results. Prior to any further 
data sorting, the age of the patients during each test was calculated in Excel (Microsoft, 
2003). Subsequent codification of the patient set was done based on specific thyroid 
function test(s). These tests were ordered by physicians as a part of the standard practice 
for diagnosing primary hypothyroidism. The first three major data sorting queries were 
based on the patients' thyroid stimulating hormone (TSH) tests, Thyroglobulin antibody 
(TgAb) test and Thyroid Peroxidase Antibody (TPO) tests, and thyroxine (free T4, total 
T4, and free T4 index) tests. These queries were done by importing the Excel data into 
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Study Population  Thyroid Function Tests 
Included 
(ICD-9 
Code)  
Chronic lymphocytic 
thyroiditis (245.2) 
Hashimoto's disease 
(245.2) 
 
Exclude
d (ICD-9 
Code) 
Malignant neoplasm of 
thyroid gland (193) 
Hypothyroidism, 
Congenital (243) 
Hypothyroidism, post 
ablative (244.1) 
Hypothyroidism, pituitary 
(244.8) 
Disorders of the pituitary 
gland and its 
hypothalamic control 
(253) 
Other and unspecified 
anterior pituitary 
hyperfunction (253.1) 
Panhypo-pituitarism 
(253.2) 
Other anterior pituitary 
disorders, including 
central hypothyroidism 
(253.4) 
Iatrogenic pituitary 
disorders (253.7) 
Other disorders of the 
pituitary and other 
syndromes of 
diencephalohypo-physeal 
origin (253.8) 
Unspecified 
dyspituitarism (253.9) 
 
Thyroid Stimulating Hormone 
(TSH)
Free triiodothyronine (T3)
Total triiodothyronine (TT-3)
Free thyroxine (T4)
Total thyroxine (TT4)
Thyroid hormone binding ratio 
(THBR)
Thyroglobulin (Tg)
Thyroxine Binding Globulin 
(TBG)
TSH Receptor Antibody (TRAb)
Reverse triiodothyronine (rT3)
Thyroglobulin antibody (TgAb)
Thyroid Peroxidase Antibody 
(TPO)
Thyroid Stimulating 
Immunoglobulin (TSI)
Thyrotropin-Binding Inhibitory 
Immunoglobulin (TBII)
 
Figure 3. Initial Patient Set Query Process. (Right table contains the investigator-
 initiated query criteria to retrieve patient identifiers, left table contains 
 the TFT keywords used by i2b2 programmers to retrieve TFT data) 
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the open-source database management software, MySQL (Oracle, 2007). 
 
HT Diagnosis: Anti-thyroid Antibody Documentation 
 Documenting an elevated level of an anti-thyroid antibody is required for HT 
diagnosis. For analysis related to antibody documentation, the initial dataset from i2b2 
was sorted into one of the following three categories: those with only TPO 
measurements, those with only TgAb measurements, and those for whom both TPO and 
TgAb were measured. 
 From patients for whom both TPO Ab and TgAb were measured, further 
categorization was performed as follows: 
 Patients who had at least one elevated TPO Ab measurement, designated as Group 
A; 
 Patients who had at least one elevated TgAb measurement, designated as Group 
B; 
 Patients who had at least one elevated TPO Ab and at least one elevated TgAb 
measurement, designated as Group C; Group C is an intersection of Groups A and 
B. 
Elevated TPO was determined to be greater than 14.9 IU/mL while elevated TgAb was 
any value greater than 24.9 IU/ml, per the reference range used by Boston Children's 
Hospital (DeBoer & LaFranchi, 2007). From the groupings above done via MySQL, two 
more groupings were made to determine the number of true positives and true negatives: 
 True Positives: defined as patients who had an elevated TPO or TgAb 
measurement, designated as Group D: Group A + Group B - Group C. 
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 True Negatives: defined as patients who had an elevation in neither TPO nor 
TgAb measurement, designated as Group E: Total patients with both TPO and 
TgAb measured - Group D. 
Sensitivity for both TPO and TgAb testing was then calculated according to the 
formulation model below, as illustrated in Table 3. Sensitivity ratios were calculated as 
'True Positives' cases divided by 'HT Diagnosed' (the sum of 'True Positives' and 'False 
Negatives') cases. 
Table 3. Formulation Model for Calculating Sensitivity of Anti-thyroid Antibodies 
 HT Diagnosed (Group D) HT Not Diagnosed (Group E) 
Positive 
True Positives 
Group A for TPO 
Group B for TgAb 
False Positives 
defined as 0 because elevated 
TPO/TgAb is a hallmark of HT 
Negative 
False Negatives 
Group D - Group A for TPO 
Group D - Group B for TgAb 
True Negatives 
Group E for both tests 
 
HT Management: TSH Measurement and Diagnosis Date 
 One of the standard confirmations in diagnosing a patient with hypothyroidism is 
through an elevation in the patient's serum TSH level (hyperthyrotropinemia). Thus, a 
patient's date of diagnosis with hypothyroidism was considered to be the first time when 
an elevated TSH was recorded. Besides initial diagnosis, hypothyroidism monitoring and 
management could be done sufficiently with periodic measurements of TSH levels, every 
6-12 months, as it is the most sensitive indicator of the thyroid status of a patient with 
primary hypothyroidism. 
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 A patient's thyroid-related profile varies depending on the age of the patient, and 
TSH is no exception. For this study, the TSH reference range, as divided by age groups, 
was based on literature values (DeBoer & LaFranchi, 2007) and reconfirmed by the 
reference range list utilized by CHB's laboratory medicine. These parameters were 
especially important since many patients were managed by CHB from childhood into 
their teenage years; for some, the management was done by CHB even well into their 
adulthood. For TSH, the parameter to determine date of diagnosis with hypothyroidism 
was set as the following: 
 Under two years old: the first date when TSH > 8.2 µIU/L. 
 Between 2-20 years old (inclusive on both end of range): first date when TSH > 
5.7 µIU/L. 
 If over 20 years old: first date when TSH > 4.2 µIU/L. 
Using the date of diagnosis, several time ranges were calculated: 
 The number of days between the diagnosis date and each laboratory test 
performed for a patient. 
 The length of each patient's study period, defined as the number of years between 
the last laboratory test recorded for a patient and the diagnosis date. 
 The age of the patient during diagnosis and during study exit (or last available test 
during this study, if the patient is still under CHB's care). 
With these determinations, the TSH measurement rate was calculated, defined as the 
number of TSH tests performed per year during the patient's time under CHB's care. 
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HT Management: Peripheral T4 Measurements 
 The TSH and peripheral T4 tests included in this query were those that were 
performed after the determined date of diagnosis. The one-time documentation of a 
simultaneous TSH and a form of peripheral T4 measurement (total T4 or free T4 or free 
T4 index) is also standard for diagnosing primary hypothyroidism. Thus, this specific 
query aimed to observe physicians' practice in ordering any subsequent TSH and 
peripheral T4 tests after a diagnosis had been documented. 
 The first order of the query was to determine the reference ranges for both 
TSH and peripheral T4 tests. These were based on literature values (DeBoer & 
LaFranchi, 2007) that were reconfirmed with CHB's laboratory medicine's reference 
ranges. Table 4 lists the reference ranges for TSH, total T4, and free T4. Free T4 Index 
(FT4I) uses the same range as total T4 in the query, with the extra step of calculating free 
T4 index through the multiplication of the value of total T4 by the corresponding value of 
the thyroid hormone binding ratio (THBR) with both tests conducted on the same 
date/same blood draw. 
Table 4. Reference Ranges for TSH and Peripheral T4 (Adapted from DeBoer & 
 LaFranchi, 2007) 
Age 
(years 
old) 
TSH 
(µIU/L) 
 Age 
(years old) 
Total T4/FT4I* 
(μg/dL) 
Free T4 
(ng/dL) 
< 2 0.8-8.2  < 2 7.2-15.7 0.8-1.8 
2-20 0.7-5.7  2-7 6.0-14.2 1.0-2.1 
> 20 0.4-4.2  8-20 4.7-12.4 0.8-1.9 
   > 20 5.3-10.5 0.9-2.5 
 * FT4I = Total T4 value x THBR value; both taken from the same blood draw 
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The manner in which the query was set-up was to apply the age categorization subquery 
first. This is especially important since the reference ranges overlap throughout the age 
range. The 2-20 years old range is inclusive at both ends of the range, i.e. patients who 
are exactly 2 or 20 years old fell within this category. 
 The next subqueries were based on the TSH and peripheral T4 tests: 
 The 'reference range' subquery was applied to determine whether a patient's 
particular TSH and peripheral T4 test results were within, below, or above the 
reference range. Values within the range were designated as 'NORMAL', below as 
'LOW', and above as 'HIGH'. 
 The 'date' subquery was applied to pair-up a TSH and a peripheral T4 if both were 
taken on the same date (this assumes that the tests were done from the same blood 
draw); this results in pair(s) of TSH-peripheral T4 tests based on a particular date 
for each patient. 
 Based on the values of the TSH-peripheral T4 pairs relative to their respective 
reference ranges, each was assigned to one of twelve possible patterns, as 
summarized in Table 5. 
 For the categorization of FT4I, an extra step was performed to find total T4 and 
THBR test pairs based upon the same date of testing then these values were 
subsequently multiple with each other, resulting in a new column indicating the 
FT4I values; this was done before any of the aforementioned test-related 
subqueries were performed. 
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  Table 5. Patterns of Simultaneous Peripheral T4 and TSH Tests 
Pattern Peripheral T4 TSH 
1 Low Not measured 
2 Low Low 
3 Low Normal 
4 Low High 
5 Normal Not measured 
6 Normal Low 
7 Normal Normal 
8 Normal High 
9 High Not measured 
10 High Low 
11 High Normal 
12 High High 
 
 Since the purpose of this query was to assess the usefulness of ordering any 
peripheral T4 tests, all data points considered must have a peripheral T4 test done on one 
particular date to be categorized into a pattern. The absence of a simultaneous 
measurement of TSH was assigned its own pattern. 
 
HT Management: Cost of Peripheral T4 and T3 Measurements 
 The purpose of the previous section's queries is to determine the number of 
unnecessary peripheral T4 measurements that were done during HT monitoring. Once 
these numbers were obtained, a peripheral measurement was categorized as either 'waste' 
or 'artifact'. The former was defined as peripheral T4 measurements that did not add to 
what their paired TSH measurements could have indicated about thyroid function. The 
latter was defined as peripheral T4 measurements that seem to indicate abnormal thyroid 
function and/or new pathology but upon further investigation of patient history, offered 
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no new conclusion. This division allows for the calculation of lost cost from peripheral 
T4 measurements during HT monitoring for each individual patient. The formula is: 
 Cost Peripheral T4 = [(# Waste Total T4 + # Artifact Total T4)(Total T4 Lab Cost)] 
+ [(# Waste FreeT4 Index + # Artifact Free T4 Index)(Free T4 Index Lab Cost)] + 
[(# Waste Free T4 + # Artifact Free T4)(Free T4 Lab Cost)]  
Lost cost from peripheral T3 measurements was also calculated because standard practice 
does not call for monitoring peripheral T3 levels, rendering any measurement to be 
unnecessary. All peripheral T3 measurements were extracted after determined date of 
diagnosis. The formula to determine this cost for each patient is as follows: 
 Cost Peripheral T3 = (# Total T3 Measured)(Total T3 Lab Cost) + (# Free T3 
Measured)(Free T3 Lab Cost) 
For both formulae, the source of the lab cost pricings was LabCorp's 2013 Book Pricing 
Listing (see Appendix B). The original goal was to use lab cost average values from the 
pricing lists of ARUP, LabCorp, and Quest Diagnostics. However, only heavily 
discounted, contract price listings were available from ARUP and Quest Diagnostics.
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RESULTS 
 
Initial Patient Dataset 
 The original raw data obtained through i2b2 based on the query criteria and 
keywords contained thyroid function test (TFT) data from January 1993 to November 
2013. There were a total number of 2,102 unique patients; 1,683 of the patients were 
female while 417 were male. The age at the time of testing ranged from 0-70 years old. 
Exclusively neonate (under 1 year old) patients were excluded from the study unless they 
were under CHB's care beyond the age of one. 97 data points from 31 patients were 
measured when the patient was under 1 year old and all but one patient did not resume 
care with CHB until entering teenage years (13 years or above). 
Table 6. Breakdown Individual TFT Counts 
TFT Name Count of Individual Measurements 
TSH (Thyroid Stimulating Hormone) 12075 
T4, Total (Thyroxine) 6198 
FT4 (Free T4) 5007 
T3, Total (Triiodothyronine) 1387 
FT3 (Free T3) 26 
rT3 (Reverse T3) 6 
TBG (Thyroxine Binding Globulin) 75 
TBII (TSH Receptor Antibody) 353 
THBR (Thyroid Hormone Binding Ratio) 4075 
Tg (Thyroglobulin) 52 
TgAb (Thyroglobulin Antibody) 1863 
TPO (Thyroid Peroxidase Autoantibody) 2079 
TSI (Thyroid Stimulating Immunoglobulin) 181 
 
 The total number of individual TFT values was 33,377 tests. 31,517 of the tests 
were taken from patients while they were aged 19 and under (94.4% of the total collected 
test data points). Male patients contributed 7,223 measurements while female patients 
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26,154 measurements. Table 6 breaks down the number of data points each TFT 
contributes to the overall total. Additionally, Figure 4 shows the proportion of patients 
who had at least one measurement of TSH and the various forms of thyroid hormone 
performed at CHB. 
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Figure 4. Proportion of Patients (from Initial Dataset) with TSH and Thyroid 
 Hormone Levels Measured 
 
Anti-thyroid Antibody Documentations 
 Based on the original dataset, a total of 1,340 patients (63.7% of total initial 
unique patients) had at least one anti-thyroid antibody measured. 19 patients had Tg Ab 
only measured throughout their time of care at CHB, 97 patients had TPO only measured, 
while 1,224 patients had both TPO and Tg Ab measured. The patient population data with 
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both TPO and Tg Ab measured (1,224 patients) was grouped according to the following 
criteria (Table 7): 
Table. 7 Patient Counts for TPO and TgAb Sensitivity Measurements 
Group Definition Patient Count 
A patients with elevated TPO measurement 716 
B patients with elevated Tg Ab measurement 565 
C patients with elevated measurements of both TPO and Tg Ab 339 
D patients with elevated TPO or elevated TgAb (True Positives: Group A + B - C) 942 
E 
patients elevated for neither TPO nor TgAb 
(True Negatives: total patient population - 
Group D) 
282 
 
 
TPO vs. TgAb Sensitivity 
 With these five groups, the sensitivity of TPO and TgAb tests was determined 
through the values in Tables 8 a and b. The sensitivity of TPO was found to be 76% while 
the sensitivity of TgAb was found to be 60%. 
 
Table 8a. TPO Values for Sensitivity Ratio Calculation 
 HT Diagnosed (942) HT Not Diagnosed (282) 
Positive True Positives: 
 
716 
False Positives: 
 
defined as 0 because elevated 
TPO/TgAb is a hallmark of HT 
Negative False Negatives: 
 
226 
 
True Negatives: 
 
282 
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Table 8b. TgAb Values for Sensitivity Ratio Calculation 
 HT Diagnosed (942) HT Not Diagnosed (282) 
Positive True Positives: 
 
565 
False Positives: 
 
defined as 0 because elevated 
TPO/TgAb is a hallmark of HT 
Negative False Negatives: 
 
377 
 
True Negatives: 
 
282 
 
HT Management: TSH Measurement 
 A total of 1,111 unique patients (52.8% of total initial unique patients) with at 
least one recorded hyperthyrotropinemia at CHB were included in this analysis. The 
patients who lacked a documented TSH elevation may reflect diagnoses performed 
outside of CHB. On the other hand, the proportion of patients with diagnosis date who 
had at least one measurement of TSH and the various forms of thyroid hormone 
performed is seen in Figure 5. 
 It was found that 8,465 of the individual TSH measurements were performed for 
the 1,111 patients, including and after the date of first TSH elevation was documented. To 
determine several statistics on the rate at which TSH was measured, 223 patients were 
excluded because their length of care at CHB was under 1 year, yielding insufficient time 
to calculate proper TSH rates. With 888 patients (679 of whom were females and 209 
were males), it was determined that the age at the  time of diagnosis ranged from 0 to 62 
years old. 860 of these patients were aged 19 or under (96.8% of the total 888 patients). 
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Figure 5. Proportion of Patients (with Diagnosis Dates) with TSH and Thyroid 
Hormone Levels Measured. 
 
The average age of diagnosis was 11.2 years old with a median age of 11 years old. 
Subsequently, the age at the time of the last documented TFT record was defined as the 
age at the time of study exit. The age ranged from 3 to 70 years old; 747 patients were 
aged 19 or under (84.1% of 888 patients). The average age of study exit was 15.7 years 
old with a median of 16 years old. Subtracting the study exit age and the diagnosis date of 
each patient allowed for the calculation of TSH rate statistics. The range of TSH 
measurement rate was from 0.167 TSH tests/year to 9 TSH tests/year. An average of 2.13 
TSH tests was done per year with a median of 2 tests/year. From the total 888 patients, 
552 patients (62.1%) had a TSH rate between 1-2 per year. 201 patients (22.6%) had a 
TSH rate that was greater than 2 but less than 3 per year while 135 patients (15.2%) had a 
TSH rate of 3 or greater per year. 
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Figure 6. Distribution of TSH Values on a Logarithmic Scale (the normal TSH 
ranges across all ages are captured by the red box) 
 
To visualize the majority of TSH values, a normalization of TSH values was performed 
with 7,741 individual TSH test values, which originated from 986 patients who had both 
a diagnosis date documented (out of the aforementioned 1,111 patients) at CHB and at 
least two or more TSH measurements taken during their period of care. TSH data points 
found within the normal range of TSH can be seen in Figure 6. 3,682 (47.6% ) of the 
TSH values fall within the normal range between 0.3µIU/L to 5.0 µIU/L, which captured 
the normal ranges across all ages. 
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HT Management: Peripheral T4 Measurement 
 The results of peripheral T4 measurement practices are tabulated in Tables 9 
a, b, c. Patterns 2, 3, 11, or 12 can be interpreted as revealing new pathology or as an 
artifact during monitoring period. If a patient's peripheral T4 measurement persistently 
stays in Patterns 2, 3, 11, or 12, the new pathology assessment was made. If these patterns 
preceded and/or succeeded Patterns 4, 6, 7, 8, or 10, they were concluded to be artifacts, 
adding no new information to what TSH alone has determined. 
 Table 9a. Total T4 and TSH Measurement Assessments and Pairing Counts 
 (includes percentage proportion of each pattern out of total test pairs) 
 
Pattern Total T4 TSH Assessment Test Pairs 
- - - TOTAL TEST PAIRS 1,349 (100%) 
1 Low Not measured 
Not standard practice 
 0 (0%) 
2 Low Low New pathology of central hypothyroidism or artifact 0 (0%) 
3 Low Normal New pathology of central hypothyroidism or artifact 11 (< 1%) 
4 Low High  
Overt hypothyroidism  
(no value added from T4) 92 (7%) 
5 Normal Not measured 
Not standard practice 
 5 (< 1%) 
6 Normal Low  
Subclinical 
hyperthyroidism  
(no value added from T4) 
116 (9%) 
7 Normal Normal  
Euthyroidism  
(no value added from T4) 620 (46%) 
8 Normal High  
Subclinical 
hypothyroidism  
(no value added from T4) 
471 (35%) 
9 High Not measured 
Not standard practice 
 0 (0%) 
10 High Low  
Overt hyperthyroidism 
(no value added from T4) 16 (1%) 
11 High Normal  
New pathology of TSH 
resistance or artifact 15 (1%) 
12 High High  
New pathology of TSH 
resistance or artifact 3 (< 1%) 
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Table 9b. Free T4 Index and TSH Measurement Assessments and Pairing Counts 
(FT4I = Total T4 x corresponding THBR; includes percentage proportion 
of each pattern out of total test pairs) 
 
Pattern Free T4  Index TSH Assessment Test Pairs 
- - - TOTAL TEST PAIRS 2,435 (100%) 
1 Low Not measured
Not standard practice 
 0 (0%) 
2 Low Low New pathology of central hypothyroidism or artifact 0 (0%) 
3 Low Normal New pathology of central hypothyroidism or artifact 32 (1%) 
4 Low High  
Overt hypothyroidism  
(no value added from FT4I) 141 (6%) 
5 Normal Not measured
Not standard practice 
 9 (< 1%) 
6 Normal Low  
Subclinical hyperthyroidism  
(no value added from FT4I) 136 (6%) 
7 Normal Normal  
Euthyroidism  
(no value added from FT4I) 1234 (51%) 
8 Normal High  
Subclinical hypothyroidism  
(no value added from FT4I) 803 (33%) 
9 High Not measured
Not standard practice 
 0 (0%) 
10 High Low  
Overt hyperthyroidism 
(no value added from FT4I) 35 (1%) 
11 High Normal  
New pathology 
of TSH resistance or artifact 38 (2%) 
12 High High  
New pathology of TSH 
resistance or artifact* 7 (< 1%) 
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Table 9c. Free T4 and TSH Measurement Assessments and Pairing Counts 
(includes percentage proportion of each pattern out of total test pairs) 
 
Pattern Free T4 TSH Assessment Test Pairs 
- - - TOTAL TEST PAIRS 2,995 (100%) 
1 Low Not measured 
Not standard practice 
 1 (~0%) 
2 Low Low New pathology of central hypothyroidism or artifact 1 (~0%) 
3 Low Normal New pathology of central hypothyroidism or artifact 13 (< 1%) 
4 Low High  
Overt hypothyroidism  
(no value added from FT4) 186 (6%) 
5 Normal Not measured 
Not standard practice 
 6 (< 1%) 
6 Normal Low  
Subclinical hyperthyroidism  
(no value added from FT4) 189 (6%) 
7 Normal Normal  
Euthyroidism  
(no value added from FT4) 1622 (54%) 
8 Normal High  
Subclinical hypothyroidism  
(no value added from FT4) 895 (30%) 
9 High Not measured 
Not standard practice 
 0 (0%) 
10 High Low  
Overt hyperthyroidism 
(no value added from FT4) 47 (2%) 
11 High Normal  
New pathology 
of TSH resistance or artifact 33 (1%) 
12 High High  
New pathology of TSH 
resistance or artifact 2 (<1%) 
 
 A total of 1,091 unique patients contributed to at least one of the three pairing 
groups. 1,349 pairs of Total T4 and TSH measurements were included in this analysis 
while 2,435 pairs of Free T4 Index and TSH measurements were included; this entailed 
the inclusion of 3,784 individual total T4 measurements and 2,435 measurements of 
THBR for calculating the Free T4 Index data points. Lastly, 2,995 Free T4 and TSH pairs 
were included. From this breakdown, it was calculated that 6,779 peripheral T4 and TSH 
measurements were utilized for this section of analysis. All peripheral tests that fell into 
Patterns 2, 3, 11, or 12 were concluded to be artifacts.
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HT Management: Cost of Peripheral T4 and T3 Measurements 
 The management period ranged from 0 to 20 years with an average of 3.5 years 
for a patient and median of 3 years for a patient. The cost of unnecessary peripheral T4 
measurements originated from 1,091 patients, contributing 6,779 peripheral T4 values. It 
was determined that an average of $399.43 was lost per patient with a median of $330.00 
per patient. The range of cost lost was $30.50/patient to $2,403.75/patient. The grand 
total of cost lost from peripheral T4 measurements amounted to $437,375.75 for CHB 
patients included in this analysis. When broken down between the contribution of wasted 
peripheral T4 and artifact peripheral T4 measurements, the former category contributed 
6,624 individual tests while the latter 155 individual tests. Wasted peripheral T4 ranged 
from $30.50/patient to $2403.75/patient with an average of $390.62 per patient of lost 
cost and a median of $317.75 per patient. The sub grand total of cost lost from wasted 
peripheral T4 was $427,732.50. On the other hand, cost lost due to artifact peripheral T4 
ranged from $30.50/patient to $471.25/patient. The average cost lost was $96.43 per 
patient with a median of $82.50 per patient. Artifact peripheral T4's contribution to the 
sub grand total of lost cost was $9,643.25. 
 For cost lost due to peripheral T3, there were 280 patients who had at least one 
free T3 and/or total T3. 11 patients had free T3 measurements while 270 had total T3 
measurements. Peripheral T3 cost lost ranged from $93.25/patient to $1,771.75/patient. 
The average was $221.79 per patient with a median of $93.25 per patient. The grand total 
of cost lost from peripheral T3 was $62,100.50. When divided, free T3 contributed 
$2,047.50 to the grand total while total T3 $60,053.00. Free T3 cost lost ranged from 
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$157.50/patient to $472.50/patient with an average of $186.13 per patient and median of 
$157.50 per patient. Total T3 cost loss's range was $93.25/patient to $1,771.75/patient 
with an average of $222.42 per patient and median of $93.25 per patient. Table 10 below 
summarizes these values accordingly. 
Table 10. Cost Loss from Unnecessary Measurements of Peripheral T4 and T3 
 Average Cost 
per Patient ($) 
Median Cost 
per Patient ($) 
Range Cost 
per Patient ($) 
Grand Total 
for Each Test 
($) 
Peripheral 
T4 399 331 31 - 2,404 437,376
Peripheral 
T3 221 93 93 - 1,772 62,101
   Grand Total 
Both Tests $499,477
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DISCUSSION 
 Through software designed and maintained by i2b2 at CHB, data were collected 
on a largely pediatric patient population. Subsequently, data management and analysis 
were performed (via i2b2, Microsoft Excel, and MySQL) on provider practices with 
regard to thyroid function test measurements in the context of diagnosing and monitoring 
Hashimoto's thyroiditis. Major analyses consisted of the determination of the sensitivity 
of anti-thyroid antibodies test for HT diagnosis, the assessment of thyrotropine level 
measurements for HT monitoring as well as the necessity and cost analysis of peripheral 
thyroid hormone measurements during HT monitoring. 
 The most commonly measured antibodies are thyroid peroxidase autoantibodies 
(TPO) and thyroglobulin antibody (TgAb). Previous studies have indicated that in adult 
populations, TPO Ab is a more sensitive test than TgAb (95% vs.60% sensitivity ratios). 
However, the applicability of these sensitivities on children is still largely unknown 
(Weetman, 2005). Several patients had no records of antibody measurements; most likely 
the documentation of these tests were done outside of CHB since an elevated antibody is 
the gateway to confirm any HT diagnosis and its subsequent monitoring. It was found 
that few patients had these antibody tests ordered according to the recommended standard 
of ordering and documenting TPO only (less than 10% of the population). However, there 
were even fewer patients who were solely tested for TgAb (less than 2%), which is a 
good indicator that at least CHB care providers are for the most part aware of TPO's 
higher sensitivity. Simultaneous ordering of both tests still prevailed as the common 
practice at CHB. It was estimated that this led to redundancy of testing for close to 1/3 of 
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the patient population; they would have benefited from the application of reflex testing 
TPO first then TgAb if necessary as recommended for standard practice to confirm an HT 
diagnosis. As for sensitivity, it was found that the sensitivity of TPO was much lower in 
CHB's pediatric population when compared to the sensitivity reported in the literature for 
adult populations (76% vs. 95%) while TgAb's sensitivity in adults also held true in 
CHB's pediatric population (both 60%). Nonetheless, TPO was still the more sensitive 
anti-thyroid antibody test compared to TgAb (76% vs. 60%). 
 The recommended standard for measuring TSH as a part of HT monitoring is 
once every 6-12 months, translating to 1-2 TSH measurements per year. From the portion 
of the population who were diagnosed at CHB, the average annual TSH rate of two 
measurements reflected that physicians followed the recommended standard. Over 4/5 of 
the study population had TSH measured less than 3 times/year and 3/5 of the population 
had 2 or fewer TSH tests done per year. It could be inferred that when caring for children, 
CHB medical providers heavily favored the higher end of the recommended monitoring 
frequency of once every six months, which is an appropriate decision since the thyroid 
profile is less stable during the pediatric age range (compared to during adulthood) and 
any aberrance could impair a child's development. A look at the effectiveness of 
monitoring outcomes was based on observing the distribution of all TSH values from the 
data collected. Less than half of these values were within the euthyroid range, indicating 
significant presence of follow-through problems in management, such as patient 
compliance and adherence issues, improper treatment dosage, etc; this brief and 
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simplified indication of an important issue would warrant a deeper investigation in future 
developments of the study. 
 Despite a generally unanimous suggestion that measuring TSH only for HT is 
sufficient without sacrificing the quality of care, the practice of ordering TSH 
simultaneously with a form of peripheral T4 is still ubiquitous. Solely measuring a form 
of peripheral T4 for HT (and even other types of primary hypothyroidism) monitoring 
was once a common practice (Schectman et al., 1990; Nordyke et al., 1998) although 
current standards dissuade this habit (as summarized in Table 2). At CHB, the practice of 
ordering a peripheral T4 only for monitoring is uncommon with less than 1% of the 6,997 
peripheral T4 test being measured without TSH. As for peripheral T4 tests that were 
paired with TSH, they were concluded to be unnecessary with none of them revealing 
new pathology or offering information beyond the measurement of TSH only. It was also 
observed that total T4 only tests (Table 9a)  had the lowest proportion of patterns 
indicating a euthyroid state when compared to the proportions of free T4 index and free 
T4 measurements (Table 9b & c). These euthyroid states were represented by Pattern 7 
(with normal peripheral T4 and TSH levels). An explanation for this is that total T4 levels 
are affected by the concentration of bound T4 in systemic circulation (influenced by a 
wide range of factors, such as genetics, other medical conditions, medications, etc.) while 
free T4 is not (Leung & Farwell, 2010); even when free T4 index and free T4 were 
compared to each other, free T4 had a higher proportion of euthyroid assessments since 
free T4 index is still based on a total T4 measurement.  
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 Based on unnecessary measurements of peripheral thyroid hormones levels, a 
substantial monetary loss was found. Peripheral T3 measurements are superfluous 
because it is an unreliable indicator of the thyroid state due to its fast clearance from the 
system, despite its more active role as a biologic effector. Peripheral T4 measurements 
should be reserved only if TSH values cannot provide the full picture on the thyroid state 
and/or give inconclusive assessments in relation to other clinical observations. These 
peripheral thyroid hormone tests, particularly nearly all peripheral T4 from this study, 
were measured simultaneously with TSH indicating the need for reflex testing 
implementation to prompt for test ordering only when necessary. Aside from prompting 
for testing, a reflex testing system should also have the ability to warn physicians during 
attempts to order unnecessary tests since many physicians habitually order superfluous 
thyroid function tests. 
 There are several efforts that have been discussed in literature to consolidate the 
difference between efficient recommended standards and provider practices in clinical 
settings. One emerging trend for tackling the lack of provider practice knowledge on 
thyroid function tests is the production of evidence-based guidelines. While in theory, this 
could work for a particular institution, it is complex and still does not resolve the 
heterogeneity of practice from one institution to another, leading to differing care 
standards should a patient have a change of medical care provider beyond an individual 
physician (Garber et al., 2012). To consolidate this problem, the American Association of 
Clinical Endocrinologists and the American Thyroid Association attempt to provide 
guidelines in diagnosing, managing, treating, and monitoring hypothyroidism based on 
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practice- and evidence based medicine that would be the gold standard for handling 
hypothyroidism. The guideline lists 52 recommendations, each with its own 
subrecommendations, based on the gender, age, race, sex, prior medical history, current 
medical condition, etc. of each patient (Garber et al., 2012). Despite the thoroughness of 
the guideline with proper amendments, it still does not resolve the problem of knowledge 
and information dissemination, i.e. the problem that non-specialists may be overwhelmed 
by the scope of knowledge they are expected to have. This caveat is further supported by 
the fact that many physicians are still not adhering to much simpler HT diagnosis and 
monitoring standards that have been established for at least a decade. 
 Another often proposed solution that has been touched upon for over a decade 
(Nordyke et al., 1998) is more relevant to this study: the implementation of reflex testing 
and the incorporation of laboratory medicine experts (who have a greater understanding 
of the purpose of each test) into the process of diagnosis and management. This would 
potentially lead to higher efficiency in terms of test ordering, medical errors reduction, 
and cost cuts in managing many diseases, including thyroid disorders. However, it would 
require a higher level of involvement from the laboratory medicine staff to provide 
feedback to physician queries as well as the physicians' additional communiqué to 
confirm or further inquire the laboratory staff's recommendations (dubbed 'curbside 
consultation'). Such a model has been approved for application and execution at 
Massachusetts General Hospital by its medical policy committee (Kratz & Laposata, 
2002). The trial period includes reflex testing in the evaluation of the underlying 
pathophysiology leading to a prolonged partial thromboplastin time (i.e. the factor 
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deficiency or inhibitor presence that would need further investigation to result in proper 
diagnoses) as well as reflexively testing total T4 and thyroid hormone binding index (to 
calculate free T4 index) when a high value of TSH is detected (Kratz & Laposata, 2002). 
The study concludes that the reflexive testing algorithms applied have minimized the 
number of unnecessary tests and patient visitations while still ensuring that all necessary 
tests are performed. The curbside consultation also facilitates a two-way communication 
between laboratory medicine and the medical staff from all departments, leading to an 
improvement in care quality and a reduction in medical errors (Kratz & Laposata, 2002). 
 Another argument for the implementation of reflex testing within the context of 
hypothyroidism rather than HT is the higher prevalence of subclinical hypothyroidism 
(relative to overt hypothyroidism) that requires long term management with medication 
adjustments such as the dosage of thyroid hormone replacement taken, if the patient and 
physician agree to treat the mild hypothyroidism (Ayala et al., 2000). Thus, it would be 
futile to order a full panel TFT for every routine visitation. For this study,  subclinical 
hypothyroidism was not included. Yet, it is an important point to stress that monitoring 
those at risk as well as diagnosing and managing those under treatment is complex feat, 
especially as the patients' age increases. This study's population generally began their 
care at Boston Children's Hospital from childhood or adolescence through adulthood. 
With a patient's age progression, a provider's practice evolves as well. In the realms of 
thyroid diseases, this is especially important for HT since it is the most common form of 
AITD in childhood and the most common thyroid disorder in iodine-sufficient areas 
(Marks & LaFranchi, 2010). An epidemiological study in Italy attempted to decipher the 
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patterns in TFT test results in childhood HT. The authors found that the first sign of goiter 
is more often the cause for subclinical hypothyroidism diagnosis rather than the 
biochemical assays, with about half of the patients having a euthyroid profile and about 
41% exhibiting clinical or mild hypothyroidism. The mildly hypothyroid children are 
then placed under routine, surveillance care with about half of the population progressing 
towards HT while the other half of the population remain euthyroid for at least 5 years 
before HT begins to manifest. The risk is amplified in patients with elevated anti-thyroid 
antibodies, with most patients developing HT from subclinical hypothyroidism within 
three years' time (Marks & LaFranchi, 2010). With the much higher sensitivity of TSH 
relative to T4, the suggested method of monitoring pediatric patients with slow HT 
manifestation remains to be the testing of TSH only (DeLuca et al., 2013; Diez et al., 
2005, Wasniewska et al., 2012) every 2-3 months for infants and 3-6 months for children 
and adolescents, rendering any other tests to be superfluous during the management of 
HT in pediatrics (Marks & LaFranchi, 2010), much like the standard literature consensus 
in care for adults. 
 52 
FUTURE DIRECTION 
 The methods and queries performed on HT patient datasets in this study will serve 
as the template in analyzing other thyroid diseases, such as congenital hypothyroidism 
and spontaneous hyperthyroidism, that are diagnosed and managed at CHB. To 
strengthen the analytical results, similar analyses will be performed on primarily adult 
populations, with patient data sets originating from the Partner's Network of Brigham and 
Women's Hospital (BWH), one of CHB's affiliated hospital networks. The utilization of 
MySQL occasionally warranted verification of query results' accuracy with Excel, 
rendering the necessity for future analyses to be done with a more sophisticated and 
bioinformatics-oriented software, such as the Statistical Analysis System (SAS). This is 
particularly important for handling data from BWH, as it is predicted that analysis of the 
BWH patient set will involve a much larger data volume. For instance, the data set 
retrieved from BWH based on the criteria used in this study, relevant to provider 
practices for patients with Hashimoto's thyroiditis, is estimated to consist of 
approximately 15,000 patients and upward of 120,000 individual thyroid function tests 
measurements. 
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APPENDIX A 
RELEVANT THYROID FUNCTION TESTS REFERENCE RANGES 
 
 
Age 
(years 
old) 
TSH 
(µIU/L) 
Age 
(years 
old) 
Total T4
(μg/dL) 
Free 
T4/FT4I* 
(ng/dL) 
TPO 
Antibody 
(IU/mL) 
Tg 
Antibody 
(IU/mL) 
< 2 0.8-8.2 < 2 7.2-15.7 0.8-1.8 0-14.9 
(for all age) 
0-24.9  
(for all age)
2-20 0.7-5.7 2-7 6.0-14.2 1.0-2.1   
> 20 0.4-4.2 8-20 4.7-12.4 0.8-1.9   
  > 20 5.3-10.5 0.9-2.5   
 
(Amended from DeBoer & LaFranchi, 2007) 
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APPENDIX B 
THYROID FUNCTION TESTS PRICE LIST 
 
 
(Amended from the 2013 LabCorp Book Pricing List without any contract discounts) 
 
 
Test Name LabCorp Price ($) 
Thyroid Stimulating Hormone (TSH) 76.25 
TSH Spec 2 152.50 
TSH Receptor Antibody (TRAb) 165.00 
T4, Total (T4) 30.50 
T4, Free (FT4) 82.50 
T3, Free (FT3) 157.50 
T3, Free Equilibrium Dialysis/HPLC-Tandem Mass 
Spectrometry 250.00 
T3, Reverse (rT3) 196.50 
T3, Total (T3) 93.25 
FT4 + T4 99.25 
FT4 + TSH 158.75 
FT4 + FT3 + TSH 316.25 
T4 + TSH 106.75 
Thyroid Panel + TSH 137.50 
Thyroid Panel 61.25 
Tg Quantitative 152.50 
Thyroid Peroxidase Autoantibody (TPO) 66.00 
Tg Antibody 84.50 
Thyroid Antibodies 150.50 
Thyroid Hormone Binding Ratio (THBR) (listed as 
T3 Uptake) 30.75 
Thyroid Stimulating Immunoglobulin (TSI) 270.00 
Thyrotropin-Binding Inhibitory Immunoglobulin 
(TBII) Not Listed 
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